WILMINGTON, Del. / Jul 30, 2024 / Business Wire / Phreesia, a leader in patient intake, outreach and activation and a member of Oracle PartnerNetwork (OPN), today announced that Phreesia is available on Oracle Healthcare Marketplace and can be integrated with the Oracle Health Electronic Health Record (EHR). Oracle Healthcare Marketplace is a centralized repository of healthcare applications offered by Oracle and Oracle partners. This new collaboration strengthens Phreesia’s existing integration with Oracle and provides expanded benefits for customers.
Organizations that use the Oracle Health EHR will now be able to leverage Phreesia’s suite of solutions, including appointment scheduling, patient registration, consent management, revenue cycle management, clinical intake workflows and referral management. Phreesia offers organizations numerous solutions to address their specific business needs, and Phreesia’s team provides dedicated, personalized support before, during and after implementation.
Oracle Healthcare Marketplace is a one-stop shop for Oracle customers seeking trusted healthcare applications offering unique clinical and business solutions, including ones that extend Oracle Health and Oracle Cloud Applications.
“We are proud that Phreesia is now available on Oracle Healthcare Marketplace, allowing us to help even more patients navigate through their care journey,” said Evan Roberts, Phreesia’s Chief Operating Officer. “Phreesia’s participation in Oracle Healthcare Marketplace further extends our commitment to the Oracle community and enables customers to easily reap the benefits of Phreesia. We look forward to leveraging the power of the Oracle Cloud and Oracle Health technologies to help us achieve our business goals.”
Phreesia has also achieved Oracle’s Industry Healthcare Expertise validation, highlighting the company’s commitment and demonstrated success in serving Oracle Health customers. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes.
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving providers, life sciences companies, payers and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
About Oracle PartnerNetwork
Oracle PartnerNetwork (OPN) is Oracle’s partner program designed to enable partners to accelerate the transition to cloud and drive superior customer business outcomes. The OPN program allows partners to engage with Oracle through track(s) aligned to how they go to market: Cloud Build for partners that provide products or services built on or integrated with Oracle Cloud; Cloud Sell for partners that resell Oracle Cloud technology; Cloud Service for partners that implement, deploy and manage Oracle Cloud Services; Industry Healthcare for partners that provide commercially available products and/or services built with Oracle Cloud and Oracle Health technologies; and License & Hardware for partners that build, service or sell Oracle software licenses or hardware products. Customers can expedite their business objectives with OPN partners who have achieved Expertise in a product family or cloud service. To learn more visit: http://www.oracle.com/partnernetwork.
Trademark
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
Last Trade: | US$25.16 |
Daily Change: | 1.32 5.54 |
Daily Volume: | 704,277 |
Market Cap: | US$1.460B |
December 09, 2024 October 28, 2024 October 01, 2024 September 04, 2024 May 30, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB